Expert Interview
Discussing Chimerix' ONC-201 in recurrent H3 K27M-mutant glioma with the Phase 3 ACTION study underway
Ticker(s): CMRXInstitution: University of Pittsburgh
- Director of Translational Neuro-Oncology at the UPMC Hillman Cancer Center & Assistant Professor of Neurological Surgery at University of Pittsburgh.
- Manages 10 patients with gliomas due to known BRAF alterations or H3 K27M-mutations per year.
- Principal investigator for numerous clinical trials for glioma and is actively involved in bringing promising brain tumor drugs from the laboratory to early-stage clinical trials.
How many patients with Glioma do you currently manage?
Added By: sara_adminWhat are your thoughts on the Phase 2 data for ONC-201?
Added By: sara_adminDo you have any criticism or praise for the design of the Phase3 ACTION study?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
